Prescribing information

 

_

Entresto is associated with reverse cardiac remodelling and improvement in cardiac function1,2

Icon for the PROVE-HF study

Dr James Januzzi, Principal Investigator of PROVE-HF, summarises the PROVE-HF study and gives a real-world example of a patient in his clinic.

 

 

 

 

 

 Icon for the EVALUATE-HF trial

 

Read the EVALUATE-HF study paper

Read the PROVE-HF study paper

 

There’s a wealth of data supporting the use of Entresto in your chronic HFrEF patients1–7

Graphic showing Clinical evidence: PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, EVALUATE-HF         

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.7

HFrEF, heart failure with reduced ejection fraction.

References

  1. Januzzi JL Jr et al. JAMA 2019; 322:1085–1095.
  2. Desai AS et al. JAMA 2019; 322:1077–1084.
  3. McMurray JJV et al. N Engl J Med 2014; 371:993–1004.
  4. Velazquez EJ et al. N Engl J Med 2019; 380:539–548.
  5. Wachter R et al. Eur J Heart Fail 2019; 21:998–1007.
  6. Pascual-Figal D et al. ESC Heart Fail 2018; 5:327–336.
  7. Entresto Summary of Product Characteristics, 2020.
ENT20-C046e(1) July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]